Skip to main content

Tags:

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Pfizer Inc.’s $16 billion acquisition of Hospira, Inc. would likely be anticompetitive.

Under the order, first announced in August 2015, the companies are required to divest Pfizer’s generic acetylcysteine inhalation solution, and Hospira’s clindamycin phosphate, voriconazole, and melphalan hydrochloride injection products.

The Commission vote approving the final order was 4-0. (FTC File No. 151 0074; the staff contact is Kari A. Wallace, Bureau of Competition, 202-326-3085)

The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.

Press Release Reference

FTC Requires Pfizer Inc. to Sell Rights to Four Products as a Condition of Acquiring Hospira, Inc.

Contact Information

MEDIA CONTACT:
Betsy Lordan
Office of Public Affairs
202-326-3707

Return to top